ABSTRACT The effects of clonidine, naloxone, and their combination on arterial blood pressure (BP), heart rate (HR), and hemodynamic and biochemical parameters were examined.in 29 patients with essential hypertension. Treatment for 3 days with 0.3 mg/day clonidine reduced BP and HR, and these effects were quickly reversed by a single injection of 0.4 mg iv naloxone in 17 of the patients (responders), but not in the remaining 12 (nonresponders). Responders had higher control values for cardiac output, stroke index, plasma renin activity (PRA), and plasma epinephrine levels than did nonresponders. Basal BP was similar in the two groups, but clonidine decreased BP, PRA, and plasma epinephrine more in responders than in nonresponders. Naloxone given during placebo treatment had no significant effects. During clonidine treatment naloxone increased BP, HR, total peripheral resistance, PRA, and plasma epinephrine and norepinephrine, and decreased stroke volume in responders, whereas in nonresponders its only effect was a small increase in HR. It is concluded that in a subset of hyperadrenergic, hypertensive patients the antihypertensive effect of clonidine involves a naloxone- central a-adrenergic stimulation involves the release of a ,8-endorphin-like material from the brain.6 A similar adrenergic-opioid interaction is present in certain forms of human hypertension. In patients with moderate essential hypertension the blood pressure-and heart rate-lowering effects of clonidine were quickly reversed by a single intravenous injection of 0.4 mg of naloxone in about one-half of the patients studied, whereas in the remaining patients naloxone was ineffective even when a larger dose was given.7 In an attempt to analyze the difference beween naloxone "responders" and "nonresponders," and to clarify the mechanism of the adrenergic-opioid interaction in the former group, we have examined hemodynamic and biochemical changes produced by clonidine, naloxone, and their combination in patients with uncomplicated essential hypertension. 
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Methods
Study population. A crossover, single-blind study was Protocol. During the drug-free control period blood pressure was measured four times a day by sphygmomanometry after 15 min of recumbent rest; the disappearance of Korotkoff sounds was used to measure diastolic pressure. Heart rate was measured from the radial pulse. The patients were given 75 gg clonidine or placebo four times a day for 3 days. Blood pressure and heart rate were measured four times a day, 1 hr after each dose of medication. On the third day, 1 hr after the second daily dose, each patient was transferred to the isotope laboratory where an intravenous line was inserted into an antecubital vein for removal of blood samples and injection of naloxone and the radioactive tracer. After 15 min of recumbent rest, blood samples were drawn for determination of plasma renin activity (PRA) and plasma levels of norepinephrine (NE) and epinephrine (E). This was followed by determination of the cardiac output (CO) as detailed below, after which a single intravenous injection of 0.4 mg of naloxone was given. Blood pressure and heart rate were measured 1, 2, 3, 5, 7, and 10 min after the injection. Immediately after the 10 min measurements a second blood sample was taken for determination of PRA and plasma catecholamines, and CO was determined again. This protocol was repeated on the third day of the second treatment period with crossover for clonidine and placebo. The sequence of treatment was determined by random allocation. To avoid interference by circadian variations in plasma levels of catecholamines,' all tests were done at around 2 P.M. Because of this, basal values are somewhat higher than in studies in which samples are taken early in the morning after patients have had a night of bed rest. Plasma samples were stored at -700 C before being assayed.
Hemodynamic parameters. CO was determined by a radiocirculographic method9"-with some modifications. In this study indium-1 13m was used as the radiotracer because of its short half-life (90 min). After a bolus intravenous injection of 10,000 cps in a volume of 0.5 ml, radioactivity was monitored precordially. The recordings were stored on magnetic tape and were played back into a compensograph operated at a paper speed of 10 mm/sec. CO was calculated from the area below the precordial radioactivity-time curve (A) with the equation 
Results
In agreement with our previous findings7 clonidine significantly reduced blood pressure and heart rate in all patients, and naloxone reversed these effects in some patients but not in others. According to their blood pressure response to naloxone during clonidine treatment, patients could be divided into naloxone responder (A mean blood pressure ¢ 10 mm Hg, n = 17) and nonresponder groups (A mean blood pressure S 10 mm Hg, n -12). This division was justified by our recent finding that in a total of 80 patients studied so far, the blood pressure response to naloxone during clonidine treatment displayed a nonuniform, bimodal distribution.* The pretreatment blood pressure and heart rate values were not significantly different in the two groups (table 1) . There was also no difference in mean ages of the groups (responders, 36.3 ± 2.4 years; nonresponders, 37.1 ± 2.0 years), in body weights, or in number of men and women in each group, but responders had a significantly shorter history of hypertension (5.6 ± 0.7 years) than nonresponders (9.3 ± 1.3 years, p S .05). Clonidine caused a significantly greater reduction in both systolic and diastolic blood pressures in the responders than in the nonresponders (table 1, figure 1 ). Naloxone did not influence blood pressure when the patients of either group were on placebo. When given during clonidine treatment, naloxone caused an abrupt rise in blood pressure to preclonidine levels in the responders, but it was ineffective in the nonresponders. Our earlier observations have indicated that naloxone remains ineffective in nonresponders even when given at three times the dose given here. 7 The selectivity of the clonidine-naloxone interaction *Farsang C, et al: Unpublished observations. Values are means and SEs. Number of patients was 17 in the responder and 12 in the nonresponder groups, except for the last three parameters, for which measurements in responders and nonresponders were done only in nine and eight (PRA) and five and four cases (NE and E).
Significant differences from corresponding values in responders: Ap .05; Bp -.005.
was examined by testing the effects of naloxone on blood pressure and heart rate after dihydrochlorothiazide treatment. Four of the responders were treated with 25 mg dihydrochlorothiazide twice daily and were given an intravenous dose of 0.4 mg naloxone on the third day 1 hr after their second daily dose of dihydrochlorothiazide. The data in table 2 indicate that, in sharp contrast to the findings in the same patients after clonidine treatment, naloxone had no effect on either blood pressure or heart rate, although dihydrochlorothiazide was as effective as clonidine in reducing blood pressure; dihydrochlorothiazide did not reduce heart rate. Clonidine decreased heart rate to the same extent in responders and nonresponders (table 1) , and naloxone did not influence heart rate during the placebo period ( figure 1, bottom) . During clonidine treatment heart rate was increased by naloxone in both groups, but the increase was significantly greater in responders than in nonresponders (figure 1).
CO was significantly higher in responders than in nonresponders (table 1) , and clonidine decreased CO in both groups (table 1, figure 2, top) . Naloxone did not influence CO either during placebo or during clonidine treatment in either group of patients. TPR was slightly but not significantly lower in responders than in nonresponders, and was not influenced by clonidine in either group ( figure 2, middle) when given to responders during clonidine treatment, stroke volume (figure 2, bottom) was unaffected by the drugs.
PRA was significantly higher in responders than in nonresponders (table 1). The effects of clonidine and naloxone on PRA are illustrated in figure 3, (top) . Clonidine decreased PRA in both groups, and the decrease was significantly greater in responders than in nonresponders. Naloxone was ineffective during the placebo period, but caused a marked increase in PRA in responders during clonidine treatment.
Mean levels of plasma catecholamines during various treatments are shown in figure 3, bottom. NE (middle panels) levels during the placebo period were not different in the two groups (see also table 1), and were not influenced by the administration of naloxone. Clonidine caused a similar reduction in plasma NE in the two groups, and naloxone, when given during clonidine treatment, caused a sharp rise in NE in the responders but was ineffective in nonresponders. In contrast to plasma NE, plasma E was more than twice as high in responders as in nonresponders (table 1) . The clonidine-induced reduction in plasma E was much greater in the former than in the latter group. Naloxone, when given during clonidine treatment, was ineffective in nonresponders but increased plasma E in responders.
The data in table 3 summarize the results of analyses of correlations between basal levels and drug-induced changes in mean blood pressure on the one hand, and biochemical parameters on the other. Since the bio- We have confirmed our earlier observation that naloxone quickly reverses the hypotensive and bradycardiac actions of clonidine in some patients with essential Values from responders and nonresponders were treated as a single group and the numbers of patients were 17 (PRA) and nine (NE and E).
Ap 6 .05, Bp < .01.
hypertension, whereas in others it has no such effects. In addition, the present findings extend these observations in three important respects by suggesting that (1) the naloxone responders represent a subset of patients with hyperadrenergic hypertension and signs of hyperkinetic cardiac function, (2) the antihypertensive action of clonidine is related to a central reduction in sympathoadrenal activity, which is greater in responders than in nonresponders, and (3) the reversal of the effects of clonidine by naloxone in responders is due to a centrally mediated increase in sympathetic tone.
When hypertensive patients are divided into naloxone responder and nonresponder groups, a number of differences become apparent (table 1) . Some of these differences are present in the absence of drug treatment and include higher levels of CO, stroke index, PRA, and plasma E in the responders. Basal blood pressure is similar in the two groups, since the effect of the higher CO is offset by a lower TPR in the responders, although the latter difference is not statistically significant. In addition, clonidine lowers blood pressure, PRA, and plasma E levels more in responders than in nonresponders. These findings suggest that the responders to naloxone represent a subset of hyperadrenergic patients with hyperdynamic cardiac function in whom the increased effectiveness of clonidine is probably related to a higher resting sympathetic tone. The significantly shorter history of hypertension in responders than in nonresponders may suggest but does not prove that the two groups represent sequential stages rather than independent subsets of hypertension. A hyperadrenergic subgroup of hypertensive patients has also been identified in a number of previous studies. 19 -20 Recently Bolli et al.2' have reported higher PRA and E levels, but similar NE levels, in a subset of hypertensive patients with increased hypotensive response to propranolol treatment. These authors have also suggested that a selective increase in plasma E rather than NE reflects sympathetic overactivity in patients with essential hypertension. 22 The selective increase in plasma E in the naloxone responders in our study is in agreement with such a possibility. The increased CO type of hypertension of the responders is also more consistent with the hemodynamic effects of E than of NE. 
